Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Helyezés a részvények között #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Részvényárfolyam
$193.62
Piaci kapitalizáció
$150.08B
Változás (1 nap)
2.76%
Változás (1 év)
184.69%
Ország
GB
Kereskedés AstraZeneca PLC (AZN)

Kategória

EPS AstraZeneca PLC (AZN) részvényre
EPS December 2025 dátummal, TTM: $13.20
AstraZeneca PLC legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi EPS mutatója (TTM) $13.20. 2024 végén a vállalat EPS mutatója $1.14 volt, csökkenés a 2023 év EPS értékéhez, amely $1.91 volt.
AstraZeneca PLC EPS története 2000 és 2026 között
EPS minden év végén
Év EPS Változtassa meg
2026 (TTM) $13.20 300.00%
2025 $3.30 189.47%
2024 $1.14 -40.31%
2023 $1.91 80.19%
2022 $1.06 2,550.00%
2021 $0.04 -96.72%
2020 $1.22 134.62%
2019 $0.52 -38.82%
2018 $0.85 -28.57%
2017 $1.19 -14.39%
2016 $1.39 24.11%
2015 $1.12 128.57%
2014 $0.49 -51.96%
2013 $1.02 -59.20%
2012 $2.50 -31.88%
2011 $3.67 31.07%
2010 $2.80 7.69%
2009 $2.60 23.81%
2008 $2.10 12.30%
2007 $1.87 -3.11%
2006 $1.93 32.19%
2005 $1.46 -98.66%
2004 $109.00 22.47%
2003 $89.00 10,753.66%
2002 $0.82 -1.20%
2001 $0.83 15.28%
2000 $0.72 0.00%
EPS hasonló cégek vagy versenytársak esetén
Vállalat EPS EPS különbség Ország
$23.00 74.24%
US
$11.10 -15.91%
US
$2.37 -82.05%
US
$7.20 -45.45%
CH
$7.30 -44.70%
US